Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence
Finalizing preclinical package to initiate clinical studies in 2022
Preclinical Proof of Concept in cancer models including combination with checkpoint inhibitors
Seeking funding by life science investors and partnerships in oncology & infectious diseases
News & Events
Immunetune Strengthens Team by Appointing Sijme Zeilemaker as Chief Executive Officer LEIDEN, the Netherlands, August 11, 2021 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced...